Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Reneo Pharmaceuticals Inc (RPHM)

Reneo Pharmaceuticals Inc (RPHM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,826
  • Shares Outstanding, K 33,421
  • Annual Sales, $ 0 K
  • Annual Income, $ -77,390 K
  • EBIT $ -62 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.68
  • Most Recent Earnings $-0.16 on 08/13/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.57
  • Growth Rate Est. (year over year) +87.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2501 +45.59%
on 09/13/24
1.9000 -4.21%
on 10/04/24
+0.3900 (+27.27%)
since 09/04/24
3-Month
1.2501 +45.59%
on 09/13/24
1.9000 -4.21%
on 10/04/24
+0.3100 (+20.53%)
since 07/03/24
52-Week
0.9801 +85.70%
on 12/14/23
9.2100 -80.24%
on 10/10/23
-5.5300 (-75.24%)
since 10/04/23

Most Recent Stories

More News
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

RPHM : 1.8200 (+5.20%)
OKUR : 18.55 (+0.22%)
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

RPHM : 1.8200 (+5.20%)
Shortened Week Due to Easter Holiday

Monday U.S. Economic Lookahead New home sales (Feb.) Featured Earnings PVH Corp. (NYSE: ...

PVH : 97.65 (-3.35%)
RPHM : 1.8200 (+5.20%)
MKC : 78.06 (-2.64%)
GME : 20.70 (-2.45%)
PRGS : 65.38 (-0.80%)
CTAS : 211.55 (-1.15%)
PAYX : 141.09 (-0.31%)
CCL : 21.28 (-0.19%)
WBA : 10.45 (-3.15%)
MSM : 82.41 (-2.15%)
OXM : 79.46 (-1.23%)
NOVC.TO : 1.75 (unch)
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the...

RPHM : 1.8200 (+5.20%)
Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.8200 (+5.20%)
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates

LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM)...

RPHM : 1.8200 (+5.20%)
Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.8200 (+5.20%)
Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.8200 (+5.20%)
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the...

RPHM : 1.8200 (+5.20%)
Reneo Pharmaceuticals Announces Senior Leadership Promotions

Michael P. Cruse appointed Chief Operating OfficerJennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 ...

RPHM : 1.8200 (+5.20%)

Business Summary

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 2.1400
2nd Resistance Point 2.0200
1st Resistance Point 1.9200
Last Price 1.8200
1st Support Level 1.7000
2nd Support Level 1.5800
3rd Support Level 1.4800

See More

52-Week High 9.2100
Fibonacci 61.8% 6.0662
Fibonacci 50% 5.0950
Fibonacci 38.2% 4.1239
Last Price 1.8200
52-Week Low 0.9801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar